BioGaia AB and University of Gothenburg discovered a new role for bacteria present in the gut: serotonin production

Often considered as our "second brain", the human gut and its resident microbiota play a crucial bidirectional role communicating the brain (central nervous system) with the gut (enteric nervous syste ...

Inside the Brutal Bulgarian Weightlifting System That Forged Champions – and Broke Bodies

Ivan Abadjiev — known as 'The Pope of Weightlifting' designed a programme that broke records, built legends and, just as ...

17 Wild Facts About The Human Body That I Absolutely Promise You Never Learned In School (Possibly Even Medical School)

"Once damaged, these hairs never grow back. You have around 3,500, and that is all you'll have throughout your entire life...
YouTube on MSN

10-Min EASY Daily Mobility Routine for Stiff Hips and Lower Back (Age 40+)

This 10-Min Easy Daily Mobility Routine is designed specifically for adults over 40 to relieve stiffness in the hips and ...

Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual ...

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two ...

Nervous sweating is a nightmare for Traitors but why do our bodies betray us like this?

Alan Carr’s glistening brow nearly gave him away on The Celebrity Traitors, but you can train yourself to dampen your ...
Le Lézard

Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies

Johnson & Johnson today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly ...

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin ...

Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficien ...